laboratori corpor
remain bullish lh post solid result mark strong growth
diagnost margin expans cro continu robust cash flow
tighten guidanc rang view weak tie larg think
question around cro book-to-bil creat opportun view
lh uniqu posit world move toward valu base care would
expect on-going benefit consum engag initi would
highlight increasingli flexibl balanc sheet reiter buy
tweak estim unh/aet maintain target ep
lab roll diagnost post revenu ahead strhe/
consensu driven acquisit strong volum volum
vs revenue/requisit modestli
vs driven head wind pama rev/req would
ex pama organ growth strong compani
continu post attract absolute/rel organ volum growth trend
covanc covanc revenu in-lin consensu
modestli us divis continu post solid organ growth
adjust oper margin expand aid launchpad save
book-to-bil area focu took modest step back vs recent
strong trend march decemb ttm
backlog stand expect convert next month
would highlight book-to-bil reflect coupl notabl
solid overal weak opportun view overal quarter
solid mark modest top bottom line beat continu strong cash
flow robust organ lab volum trend narrow guidanc remain
bullish view lh uniqu posit world move toward valu
think pama present meaning share gain opportun view weak
around covanc overdon addit balanc sheet strong
robust food solut sale provid increment firepow
comment aet recent contract unitedhealthcar
buy aetna aet nr open
network present opportun risk lh consist
indic contract chang like head wind expect
howev see move toward valu base contract someth
like gain increas momentum time meaning
posit larg independ view compani qualiti data
tr target
laboratori corpor america hold
analytics/integr broad servic offer increas connect cost
effect meaning competit advantag leav lh well-
posit valu base contract gain increment traction
move ahead grow patient healthcar cost respons increas demand
transpar premium conveni engag healthcar decis maker patient
connect grow increasingli import compani continu invest engag
efficiency/access tool labcorp pre-check labcorp express labcorp patient mobil app
help directli improv user experi addit spirit draw closer patient
lh home collect devic continu make headway track commerci avail
later year walgreen hold collabor store plan
ramp addit locat earli return encourag higher percentag new patient
attract patient satisfact would expect on-going growth walgreen locat
forese futur view attract growth driver/effici use capit
strong balanc sheet adjust estim cffo came
strong respect quarter compani bought back stock
paid debt leav leverag net-debt ttm adjust ebitda addit
lh enjoy financi flexibl recent sale food solut busi
view compani extrem well posit market industri pressur pama
potenti move toward valu base care could drive acceler opportun
ep unchang trim ep reflect
sale food solut modestli conserv pama assumpt expect
net impact recent unh/aet contract chang
page
laboratori corpor america hold
servic
revenu
incom equiti invest
revenu
laboratori corpor america mm
page
laboratori corpor america hold
headquart burlington nc laboratori corpor america hold labcorp one
largest independ clinic laboratori broad offer includ routin test
blood chemistri urinalys pap hiv substance-abus etc specialti test oncolog hiv
genotyp phenotyp diagnost genet clinic research trial compani also
opper cro busi extend servic offer includ clinic research provid
meaning intern presenc recent chiltern acquisit expand cro servic
clinic lab remain integr part healthcar deliveri model diagnost test critic
compon treatment decis process combin covanc busi lh boast
signific scale divers servic offer uniqu posit area person medicin
potenti risk-bas reimburs system diversifi revenu stream custom
base also meaning lower reimburs risk one custom repres revenu
govern pay addit signific clinic horsepow geograph
diversif provid platform addit growth opportun time
valuat risk
price target base stock trade adjust ep premium
current multipl industri peer hold given labcorp sizabl esoter presenc
solid cash flow gener attract cross-sel opportun covance/chiltern view
appropri addit believ effici initi aggress focu cost
control could provid support risk rate price target includ advers shift
reimburs pama poor integr acquisit pressur econom uncertainti
perform covanc increas competit
compani mention note
david macdonald herebi certifi view express research report accur reflect
person view subject compani secur also certifi
receiv direct indirect compens exchang express
specif recommend report
